Results 201 to 210 of about 15,937 (243)
The Use of Vasodilator Therapy in Fontan Patients: A Single-Centre Experience. [PDF]
Children (Basel)Faccini A +10 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Expert Review of Cardiovascular Therapy, 2004
Bosentan (Tracleer, Actelion Pharmaceuticals Ltd) is an oral dual endothelin receptor antagonist approved for use in functional class III to IV pulmonary arterial hypertension. In two placebo-controlled trials, patients receiving bosentan showed improved functional class, 6-minute walk distance and hemodynamics over a 12- to 16-week period.
Kelly, Chin, Richard, Channick
openaire +3 more sources
Bosentan (Tracleer, Actelion Pharmaceuticals Ltd) is an oral dual endothelin receptor antagonist approved for use in functional class III to IV pulmonary arterial hypertension. In two placebo-controlled trials, patients receiving bosentan showed improved functional class, 6-minute walk distance and hemodynamics over a 12- to 16-week period.
Kelly, Chin, Richard, Channick
openaire +3 more sources
Expert Opinion on Pharmacotherapy, 2010
Pulmonary arterial hypertension (PAH) is a morbid condition with high mortality if left untreated. Bosentan is an effective treatment option for group 1 pulmonary arterial hypertension. Bosentan improves exercise tolerance and functional class and delays the time to clinical worsening in these patients.
Michael A, Mathier, David, Ishizawar
openaire +3 more sources
Pulmonary arterial hypertension (PAH) is a morbid condition with high mortality if left untreated. Bosentan is an effective treatment option for group 1 pulmonary arterial hypertension. Bosentan improves exercise tolerance and functional class and delays the time to clinical worsening in these patients.
Michael A, Mathier, David, Ishizawar
openaire +3 more sources
Heart Disease, 2003
Bosentan is the first endothelin (ET) receptor antagonist approved by the Food and Drug Administration for the management of pulmonary arterial hypertension (PAH). In patients with World Health Organization Class III and IV PAH, bosentan has demonstrated improvement in dyspnea and exercise tolerance.
openaire +2 more sources
Bosentan is the first endothelin (ET) receptor antagonist approved by the Food and Drug Administration for the management of pulmonary arterial hypertension (PAH). In patients with World Health Organization Class III and IV PAH, bosentan has demonstrated improvement in dyspnea and exercise tolerance.
openaire +2 more sources
Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension [PDF]
European Heart Journal, 2006 Steeve Provencher +2 more
exaly +2 more sources